Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
Propranolol blocks the receptors that adrenaline binds to and impairs the ability to learn or remember information.
The finding
What the evidence shows
The researchers named are real and so is the finding, but it is narrower than described. In the 1994 Cahill and McGaugh study, propranolol removed the memory boost people normally get for an emotionally arousing story while leaving memory for a matched neutral story intact. A meta-analysis of 18 experiments in healthy adults found the same selective pattern, reduced recall of negative or emotionally charged material. Saying a beta blocker blocks learning in general goes past what the evidence shows.
Read the supporting source · www.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that Propranolol blocks the receptors that adrenaline binds to and impairs the ability to learn or remember information?
Partly. The claim stretches what the evidence shows. The researchers named are real and so is the finding, but it is narrower than described. In the 1994 Cahill and McGaugh study, propranolol removed the memory boost people normally get for an emotionally arousing story while leaving memory for a matched neutral story intact. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 1:36:09. The supporting source is ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.